Fig. 5.
Fig. 5. ELISA analysis of diluted sera (1:1000) showing the presence of antibodies directed at SPAN-Xb in patients with hematologic malignancies but not in healthy donors. / (A) ELISA for SPAN-Xb antibodies in patients with lymphoproliferative disorders (sample 1, mean ± 2 SD from 24 healthy donors; samples 2-45, MM; samples 46-57, CLL). (B) ELISA for SPAN-Xb antibodies in patients with myeloproliferative disorders (sample 1, mean ± 2 SD from 24 healthy donors; samples 2-21, CML; samples 22-23, AML). *Samples with signals in excess of mean ± 2 SD from 24 healthy donors.

ELISA analysis of diluted sera (1:1000) showing the presence of antibodies directed at SPAN-Xb in patients with hematologic malignancies but not in healthy donors.

(A) ELISA for SPAN-Xb antibodies in patients with lymphoproliferative disorders (sample 1, mean ± 2 SD from 24 healthy donors; samples 2-45, MM; samples 46-57, CLL). (B) ELISA for SPAN-Xb antibodies in patients with myeloproliferative disorders (sample 1, mean ± 2 SD from 24 healthy donors; samples 2-21, CML; samples 22-23, AML). *Samples with signals in excess of mean ± 2 SD from 24 healthy donors.

Close Modal

or Create an Account

Close Modal
Close Modal